"Following the gut The Anatara/Zoetis deal is a company maker"

Pitt Street Research Report
Pitt Street Research Report
Melbourne, Mar 19, 2019 AEST (ABN Newswire) - Pitt Street Research has released its latest initiating research and valuation report on Anatara Lifesciences (ASX:ANR) (ANR). The report provides a $1.34 per share base case and a $3.61 optimistic case using a probability-weighted DCF valuation approach.

Key Points

- Anatara is currently trading way below this valuation range

- Potential for Anatara to be re-rated by the market as GaRP progresses and as Zoetis gains regulatory approvals and launches Detach in North America, Europe and Asia.

- The opportunity for Detach is remarkable, given the size and scale of Zoetis' animal health portfolio

- Interest from one of the largest animal health companies worldwide reaffirms the credibility of the bromelain technology and reduces Anatara's cost burden, while providing a stream of cash flow to help the company move forward with its plans in human GI health

To view the research report, please visit:

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.



Anatara Lifesciences Ltd
E: info@anataralifesciences.com
WWW: www.anataralifesciences.com

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 15) (Last 30 Days: 67) (Since Published: 2648)